HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid Tumors

Loading news article.

HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid Tumors | WAPE

Article summary